Literature DB >> 12868547

Antibacterial resistance in Streptococcus pneumoniae and Haemophilus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999-2000.

A M Schito1, G C Schito, E Debbia, G Russo, J Liñares, E Cercenado, E Bouza.   

Abstract

Antibacterial resistance was evaluated among Streptococcus pneumoniae (n=252) and Haemophilus influenzae (n=202) from two centres in Spain (Barcelona and Madrid) and two centres in Italy (Genoa and Catania) collected during 1999-2000 as part of the ongoing PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) international surveillance program. Pneumococcal nonsusceptibility to penicillin G was found to be considerably higher in Spain (53.4%) than in Italy (15.1%), whereas erythromycin A resistance was higher in Italy (42.9%) than in Spain (28.6%). Among macrolide-resistant isolates investigated for resistance genes, the prevalence of mefA was higher among isolates from Italy (20/51, 39.2%) than among Spanish isolates (2/38, 5.3%). All other macrolide-resistant isolates possessed ermB. Telithromycin possessed good anti-pneumococcal activity against isolates from both countries (MIC90 0.03 mg/L [Spain]; 0.25 mg/L [Italy]), irrespective of resistance to other antibacterials. Beta-lactamase production among H. influenzae was low: Spain, 10.9%; Italy, 1.8%. With the exception of ampicillin and co-trimoxazole, all H. influenzae isolates were highly susceptible to the antibacterials tested, and all were inhibited by telithromycin at a concentration of < or = 2 mg/L. The findings of PROTEKT 1999-2000 highlight the importance of local resistance patterns in guiding the choice of empirical antibacterials for community-acquired respiratory tract infections.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12868547     DOI: 10.1179/joc.2003.15.3.226

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  7 in total

1.  Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  Tatiana Bogdanovich; Catherine Clark; Lois Ednie; Gengrong Lin; Kathy Smith; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Antistreptococcal activity of AR-709 compared to that of other agents.

Authors:  Kathy Smith; Lois M Ednie; Peter C Appelbaum; Stephen Hawser; Sergio Lociuro
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

3.  Activity of LBM415 compared to those of 11 other agents against Haemophilus species.

Authors:  Tatiana Bogdanovich; Kathy A Smith; Catherine Clark; Glenn A Pankuch; Gengrong Lin; Pamela McGhee; Bonifacio Dewasse; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.

Authors:  Vlatka Matic; Klaudia Kosowska; Bulent Bozdogan; Linda M Kelly; Kathy Smith; Lois M Ednie; Gengrong Lin; Kim L Credito; Catherine L Clark; Pamela McGhee; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.

Authors:  Klaudia Kosowska; Dianne B Hoellman; Gengrong Lin; Catherine Clark; Kim Credito; Pamela McGhee; Bonifacio Dewasse; Bülent Bozdogan; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 6.  Drug treatment of pneumococcal pneumonia in the elderly.

Authors:  Sridhar Neralla; Keith C Meyer
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 7.  Role of antimicrobial agents in the management of exacerbations of COPD.

Authors:  Sat Sharma; Nicholas Anthonisen
Journal:  Treat Respir Med       Date:  2005
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.